Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 282

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 282
---
 located in the town of Portland, New York. WEED’s acquisition
of this ~43 acre property with ~2000 ft. of Lake Erie waterfront also comes with the “unlimited water extractions rights”
from Lake Erie related to the property, along with a complete wastewater management plant. WEED’s initial plan is to utilize the
property to access the hemp and infused beverage markets as our property in the middle of the largest concord grape producing region of
the United States. In the future, WEED may look to use the unique property infrastructure to build a luxury condos & resort development
in the most natural settings to be ESG compliant in conjunction to WEEDs forming its Social Equity Advisory Council (SEAC) to create Diversity
& Equality in our industry. This project is only in its conceptual stage, no funding or plans have been developed other than the proposed
name: The 4 Winds Luxury condos & resort to be “Cannabis Friendly” which would be a “FIRST” in the nation.

Third, WEED established
WEED Australia Ltd. and its wholly owned Cannabis Institute of Australia (C.I.A.) in Australia in March of 2017, for the purpose of conducting
cannabis and hemp research and potentially developing products and educational services in and for Australians as stated above. C.I.A.
is a non-profit entity formed for the purpose of conducting cannabis and hemp research with universities and other non-profits to protect
all intellectual rights, properties and usage in our highly regulated industry. The C.I.A. has the potential to develop products in Australia
for domestic research and development of products, services and educational purposes to all seven States and territories, including Tasmania,
to be marketed globally.

21

Our first business opportunity
was, and continues to be, through our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), where we are focused on the development
and application of cannabis-derived compounds for the treatment of human disease and animal ailments. To that end Sangre, was working
on a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic
classification of the entire plant. Sangre completed a 1-2 year Pilot Study in 2017 & 2018 at the University of Texas-Galveston thru
Industrial Metagenomics at a cost of nearly $1 million USD. Sangre completed the pilot study with 30 cultivars from strains collected
worldwide that included 30 strains (